bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but it is important to look past the technical jargon. Here is a simple breakdown of what you need to know.

1. What does this company actually do?

In plain English, bioAffinity focuses on early cancer detection. Their main product, CyPath® Lung, is a lab test designed to help doctors diagnose lung cancer.

Instead of just using imaging, their test analyzes a patient’s mucus sample. They use a special fluorescent dye that sticks to cancer cells. Under a microscope, these cells glow in specific patterns. Automated software then analyzes these patterns to spot cancer. The company wants to help high-risk patients—especially those with unclear lung spots—get diagnosed and treated sooner.

2. What’s happening with this new offering?

The company is raising about $3.4 million by selling "units." Each unit includes one share of stock and one warrant.

• The Price: Each unit costs $5.48.
• What are Warrants? A warrant lets you buy one extra share of stock for $5.48. You can use these immediately, and they expire in five years.
• The "Best Efforts" Catch: This is a "best efforts" deal. There is no minimum amount the company must raise. If demand is low, they might raise much less than $3.4 million. This could force them to cut back on research or sales.
• Immediate Dilution: This is important for new investors. If you buy in at $5.48, you are paying a premium. The company’s "net tangible book value"—the value of its assets minus its debts—is only $0.76 per share after this deal. You are paying $4.72 more than the current value of the company’s assets. You are paying for future potential, not what the company is worth today.

3. What are the main risks?

Investing in small biotech firms is inherently risky. Here is what to watch:

• The Cash Crunch: The company has lost money for years and has a total deficit of over $60 million. They rely on outside funding to stay open. Because they do not make enough profit to cover costs, they must frequently issue more shares. This reduces your ownership percentage in the company.
• Hidden "Overhang": Besides the new shares, there are about 940,000 warrants held by previous investors. These have an average exercise price of $41.60. While that is much higher than the current price, it represents a large pool of potential shares that could be issued later, further reducing your ownership stake.
• Regulatory & Legal Hurdles: As a public company, bioAffinity must follow strict rules. If they fail to follow SEC or Nasdaq regulations, they could face penalties or lose investor trust. Also, biotech stocks are volatile and often swing wildly based on clinical trial results or government approvals.
• Delisting Risk: The company must follow Nasdaq rules, including keeping their share price above $1.00. If the price stays below this for too long, they could be removed from the exchange. This would make it much harder to sell your shares.

4. The Bottom Line

bioAffinity is a "micro-cap" company, which means it is a small, volatile business. They are currently trying to grow sales for CyPath® Lung, and this cash raise shows they need more money to keep running.

Who’s running the show? The company is led by CEO Maria Zannes.

Where to find them: They trade on the Nasdaq under the symbol BIAF.

How to make your final decision: Before you put any money down, take 10 minutes to look at the "Risk Factors" section in the company’s official Prospectus on the SEC’s EDGAR website. It’s not light reading, but it is the most honest document the company is legally required to produce.

Disclaimer: I am an AI, not a financial advisor. Offerings are risky. Never invest money you cannot afford to lose, and always conduct your own due diligence before making any financial decisions.